Personalized Medicine: A Perk of Privilege?
Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefit...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2009-07, Vol.86 (1), p.21-23 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 21 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 86 |
| creator | Griggs, JJ |
| description | Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefits of these advances. Given the inequities in our health‐care system, there is no assurance that expanding research into molecular and genomic testing will benefit everyone equally. Moreover, widespread adoption of new and emerging technologies poses challenges for an already overtaxed health‐care system.
Clinical Pharmacology & Therapeutics (2009); 86, 1, 21–23 doi:10.1038/clpt.2009.75 |
| doi_str_mv | 10.1038/clpt.2009.75 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67394965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67394965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4055-5a79e7b58ee8732990f9fadc497584779ef8295db763f836694cd54a2e4c8383</originalsourceid><addsrcrecordid>eNp9kDtPwzAQgC0EoqWwMaMssECKHduxzYKqiJdURIbsluvYyJAmxW5B5dfjqBFsTKe7-3SPD4BTBKcIYn6tm9V6mkEopozugTGiOEtziuk-GMNYTUWG8xE4CuEtpkRwfghGSFCcIyTG4LI0PnStaty3qZNnUzvtWnOTzJLYeE86m5TefbrGvJrbY3BgVRPMyRAnoLq_q4rHdP7y8FTM5qkmkNKUKiYMW1BuDGc4EwJaYVWtiWCUExablmeC1guWY8txnguia0pUZojmmOMJuNiNXfnuY2PCWi5d0KZpVGu6TZA5w4KI-OIEXO1A7bsQvLFy5d1S-a1EUPZuZO9G9m4k6_GzYe5msTT1HzzIiMD5AKigVWO9arULv1yG4k4hWOTYjvuKXrb_LpVFWRXzsurTeMIPtdx7cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67394965</pqid></control><display><type>article</type><title>Personalized Medicine: A Perk of Privilege?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Griggs, JJ</creator><creatorcontrib>Griggs, JJ</creatorcontrib><description>Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefits of these advances. Given the inequities in our health‐care system, there is no assurance that expanding research into molecular and genomic testing will benefit everyone equally. Moreover, widespread adoption of new and emerging technologies poses challenges for an already overtaxed health‐care system.
Clinical Pharmacology & Therapeutics (2009); 86, 1, 21–23 doi:10.1038/clpt.2009.75</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2009.75</identifier><identifier>PMID: 19536119</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Biological and medical sciences ; Delivery of Health Care - legislation & jurisprudence ; Delivery of Health Care - standards ; Genetic Counseling - legislation & jurisprudence ; Genetic Counseling - standards ; Genetic Testing - legislation & jurisprudence ; Genetic Testing - standards ; Humans ; Medical sciences ; Patient Rights - legislation & jurisprudence ; Patient Rights - standards ; Personal Health Services - legislation & jurisprudence ; Personal Health Services - standards ; Pharmacology. Drug treatments</subject><ispartof>Clinical pharmacology and therapeutics, 2009-07, Vol.86 (1), p.21-23</ispartof><rights>2009 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4055-5a79e7b58ee8732990f9fadc497584779ef8295db763f836694cd54a2e4c8383</citedby><cites>FETCH-LOGICAL-c4055-5a79e7b58ee8732990f9fadc497584779ef8295db763f836694cd54a2e4c8383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2009.75$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2009.75$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21653997$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19536119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Griggs, JJ</creatorcontrib><title>Personalized Medicine: A Perk of Privilege?</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefits of these advances. Given the inequities in our health‐care system, there is no assurance that expanding research into molecular and genomic testing will benefit everyone equally. Moreover, widespread adoption of new and emerging technologies poses challenges for an already overtaxed health‐care system.
Clinical Pharmacology & Therapeutics (2009); 86, 1, 21–23 doi:10.1038/clpt.2009.75</description><subject>Biological and medical sciences</subject><subject>Delivery of Health Care - legislation & jurisprudence</subject><subject>Delivery of Health Care - standards</subject><subject>Genetic Counseling - legislation & jurisprudence</subject><subject>Genetic Counseling - standards</subject><subject>Genetic Testing - legislation & jurisprudence</subject><subject>Genetic Testing - standards</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Patient Rights - legislation & jurisprudence</subject><subject>Patient Rights - standards</subject><subject>Personal Health Services - legislation & jurisprudence</subject><subject>Personal Health Services - standards</subject><subject>Pharmacology. Drug treatments</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAQgC0EoqWwMaMssECKHduxzYKqiJdURIbsluvYyJAmxW5B5dfjqBFsTKe7-3SPD4BTBKcIYn6tm9V6mkEopozugTGiOEtziuk-GMNYTUWG8xE4CuEtpkRwfghGSFCcIyTG4LI0PnStaty3qZNnUzvtWnOTzJLYeE86m5TefbrGvJrbY3BgVRPMyRAnoLq_q4rHdP7y8FTM5qkmkNKUKiYMW1BuDGc4EwJaYVWtiWCUExablmeC1guWY8txnguia0pUZojmmOMJuNiNXfnuY2PCWi5d0KZpVGu6TZA5w4KI-OIEXO1A7bsQvLFy5d1S-a1EUPZuZO9G9m4k6_GzYe5msTT1HzzIiMD5AKigVWO9arULv1yG4k4hWOTYjvuKXrb_LpVFWRXzsurTeMIPtdx7cg</recordid><startdate>200907</startdate><enddate>200907</enddate><creator>Griggs, JJ</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200907</creationdate><title>Personalized Medicine: A Perk of Privilege?</title><author>Griggs, JJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4055-5a79e7b58ee8732990f9fadc497584779ef8295db763f836694cd54a2e4c8383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Delivery of Health Care - legislation & jurisprudence</topic><topic>Delivery of Health Care - standards</topic><topic>Genetic Counseling - legislation & jurisprudence</topic><topic>Genetic Counseling - standards</topic><topic>Genetic Testing - legislation & jurisprudence</topic><topic>Genetic Testing - standards</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Patient Rights - legislation & jurisprudence</topic><topic>Patient Rights - standards</topic><topic>Personal Health Services - legislation & jurisprudence</topic><topic>Personal Health Services - standards</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Griggs, JJ</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Griggs, JJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalized Medicine: A Perk of Privilege?</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2009-07</date><risdate>2009</risdate><volume>86</volume><issue>1</issue><spage>21</spage><epage>23</epage><pages>21-23</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Advances in molecular testing and genomic technology offer promise in helping identify people at risk of developing disease and those most (or least) likely to benefit from risk reduction and treatment strategies. Yet not all of those who are eligible for such technologies have access to the benefits of these advances. Given the inequities in our health‐care system, there is no assurance that expanding research into molecular and genomic testing will benefit everyone equally. Moreover, widespread adoption of new and emerging technologies poses challenges for an already overtaxed health‐care system.
Clinical Pharmacology & Therapeutics (2009); 86, 1, 21–23 doi:10.1038/clpt.2009.75</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>19536119</pmid><doi>10.1038/clpt.2009.75</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2009-07, Vol.86 (1), p.21-23 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67394965 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Delivery of Health Care - legislation & jurisprudence Delivery of Health Care - standards Genetic Counseling - legislation & jurisprudence Genetic Counseling - standards Genetic Testing - legislation & jurisprudence Genetic Testing - standards Humans Medical sciences Patient Rights - legislation & jurisprudence Patient Rights - standards Personal Health Services - legislation & jurisprudence Personal Health Services - standards Pharmacology. Drug treatments |
| title | Personalized Medicine: A Perk of Privilege? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A41%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalized%20Medicine:%20A%20Perk%20of%20Privilege?&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Griggs,%20JJ&rft.date=2009-07&rft.volume=86&rft.issue=1&rft.spage=21&rft.epage=23&rft.pages=21-23&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2009.75&rft_dat=%3Cproquest_cross%3E67394965%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67394965&rft_id=info:pmid/19536119&rfr_iscdi=true |